A to Z / Growth hormone

Tesamorelin

Also known as Egrifta, TH9507.

Best known for The only GHRH analogue with a current approval

Evidence★★★★☆

Safety dataWell characterised

Route injectable (subcutaneous)

United StatesFDA approved

AustraliaSchedule 4; captured by Appendix D cl.5 class entry (GHRHs)

as at 16 September 2026

What it is

Tesamorelin is a synthetic analogue of growth hormone releasing hormone, approved in the United States as Egrifta for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy.

It has a special place in this book as the only compound in the growth hormone section holding a current approval. That makes it a useful reference point for understanding CJC-1295, ipamorelin and sermorelin.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Sermorelin, CJC-1295 (with DAC), Somatropin, Ipamorelin

Related entries

SermorelinThe GHRH analogue once approved, now compounded · Evidence ★★★★☆
CJC-1295 (with DAC)Half of the classic clinic growth hormone stack · Evidence ★★☆☆☆
SomatropinHuman growth hormone itself, the benchmark for every secretagogue · Evidence ★★★★★
IpamorelinThe "clean" growth hormone secretagogue · Evidence ★★☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Tesamorelin. It is not medical advice and not a recommendation to use it.